Enteropathy-Associated T-Cell Lymphoma research hub

A safety study of PF-08046045/SGN-35T in adults with advanced cancers

This study is looking at a new medicine for people with certain advanced cancers, including different types of lymphoma. It's the first time this medicine is being given to people, to check if it's safe and how it works in the body.

Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study

This study looks at a special scan before CAR T-cell therapy for lymphoma. It uses a tracer to see how certain proteins in lymphoma cells react. The aim is to understand how this scan can predict treatment success and help tell the difference between active lymphoma and normal swelling.

RadiothErapy priMIng for CAR-T

This study is for people with a type of blood cancer called Diffuse Large B Cell Lymphoma, whose condition has come back or not responded to previous treatments. It looks at giving a small amount of radiotherapy before a special treatment called CAR-T to see if it makes the CAR-T treatment work better.

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

This study is testing a new medicine called epcoritamab, sometimes with other treatments, for people with B-cell non-Hodgkin lymphoma. Doctors want to check if it's safe and if it helps shrink the cancer. It's given by injection under the skin.

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

This study looks at a new combination of two drugs, tafasitamab and lenalidomide, for adults in the UK with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It's for those whose cancer has returned or hasn't responded well to previous treatments and who can't have a stem cell transplant.

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

This study looks at how a new drug called epcoritamab works for adults with Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in real-life settings. It aims to see how well it treats these blood cancers when given as part of regular care.

Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

This study is testing if adding a new drug, acalabrutinib, to standard chemotherapy (R-CHOP) helps people with a type of lymphoma called Diffuse Large B-cell Lymphoma (DLBCL) who haven't had treatment before. Researchers want to see if this new combination works better.

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

This study looks at new treatments for a type of blood cancer called Diffuse Large B-Cell Lymphoma in older patients who can't have standard chemotherapy. It tests a drug called epcoritamab, with or without another drug called lenalidomide, to see how well they work and if they are safe.

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

This study compares a new medicine called epcoritamab with standard chemotherapy for a type of lymphoma (DLBCL) that hasn't responded to earlier treatments. It aims to see if epcoritamab is safer and more effective for patients who can't have or have already had a stem cell transplant.

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study looks at a new combination of treatments for a type of lymphoma called diffuse large B-cell lymphoma. It combines standard chemotherapy with a newer drug called pembrolizumab to see if it works better for people whose lymphoma has come back or hasn't responded to previous treatment.

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

This study is looking into a new tablet medicine, ABBV-525, for adults with certain B-cell cancers like lymphoma and leukaemia. It aims to check its safety, how well the body handles it, and if it could help treat these conditions.

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.

A Long-term Extension Study of PCI-32765 (Ibrutinib)

This study offers ongoing access to a drug called ibrutinib for people already using it for certain blood cancers and conditions, who are still benefiting. It also helps gather more long-term information on how safe and effective ibrutinib is.

INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies

A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

CC-122 Rollover Study

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

This study is testing a new drug, Zilovertamab Vedotin, for children and young adults aged 6 months to 25 years with certain blood cancers (like some types of leukaemia and lymphoma) and solid tumours (like neuroblastoma and Ewing sarcoma) that have come back or not responded to previous treatments.